Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.

Breast cancer research and treatment - 1 Nov 2007

Ozcelik Hilmi, Pinnaduwage Dushanthi, Bull Shelley B, Andrulis Irene L

Abstract excerpt

Alterations of TP53 and ERBB2 have been shown to play important roles in the prognosis of breast cancer. The primary objective of this study is to characterize TP53 mutation types in node negative breast cancer and investigate their prognostic value, alone and in combination with ERBB2 amplification status. TP53 mutational status (exons 2-10) and ERBB2 amplification status were determined in tumor specimens from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Gene Expression Regulation, Neoplastic

Share to Lymphatic Metastasis

Share to Receptor, ErbB-2

Share to Survival Rate

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 17221157
DOI: 10.1007/s10549-006-9452-0

Genes

TP53
ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.PMID 17221157Read ↗

Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.Semantic proximity Read ↗

Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trialSemantic proximity Read ↗

TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients.Semantic proximity Read ↗

TP53Mutation is an Independent Prognostic Marker for Poor Outcome in Both Node-negative and Node-positive Breast CancerSemantic proximity Read ↗

The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast CancerSemantic proximity Read ↗

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.Semantic proximity Read ↗

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.Semantic proximity Read ↗

Distinct tumor protein p53 mutants in breast cancer subgroups.Semantic proximity Read ↗

Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations.Semantic proximity Read ↗

p53 Dysregulation in Breast Cancer: Insights on Mutations in the TP53 Network and p53 Isoform Expression.Semantic proximity Read ↗

Mutations in p53, p53 protein overexpression and breast cancer survival.Semantic proximity Read ↗

Correlating p53 immunostaining patterns with somatic TP53 mutation and functional properties of mutant p53 in triple‐negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.